rs544654228
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_002878.4(RAD51D):c.493C>T(p.Arg165Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000688 in 1,612,350 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R165Q) has been classified as Benign.
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000071 ( 0 hom. )
Consequence
RAD51D
NM_002878.4 missense
NM_002878.4 missense
Scores
9
9
Clinical Significance
Conservation
PhyloP100: 4.82
Genes affected
RAD51D (HGNC:9823): (RAD51 paralog D) The protein encoded by this gene is a member of the RAD51 protein family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51, which are known to be involved in the homologous recombination and repair of DNA. This protein forms a complex with several other members of the RAD51 family, including RAD51L1, RAD51L2, and XRCC2. The protein complex formed with this protein has been shown to catalyze homologous pairing between single- and double-stranded DNA, and is thought to play a role in the early stage of recombinational repair of DNA. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream ring finger and FYVE-like domain containing 1 (RFFL) gene. [provided by RefSeq, Jan 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAd4 at 8 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD51D | NM_002878.4 | c.493C>T | p.Arg165Trp | missense_variant | 6/10 | ENST00000345365.11 | NP_002869.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51D | ENST00000345365.11 | c.493C>T | p.Arg165Trp | missense_variant | 6/10 | 1 | NM_002878.4 | ENSP00000338790.6 | ||
ENSG00000267618 | ENST00000593039.5 | c.16C>T | p.Arg6Trp | missense_variant | 2/7 | 2 | ENSP00000466834.1 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152202Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
8
AN:
152202
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000404 AC: 10AN: 247668Hom.: 0 AF XY: 0.0000373 AC XY: 5AN XY: 133870
GnomAD3 exomes
AF:
AC:
10
AN:
247668
Hom.:
AF XY:
AC XY:
5
AN XY:
133870
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000705 AC: 103AN: 1460030Hom.: 0 Cov.: 31 AF XY: 0.0000730 AC XY: 53AN XY: 726106
GnomAD4 exome
AF:
AC:
103
AN:
1460030
Hom.:
Cov.:
31
AF XY:
AC XY:
53
AN XY:
726106
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152320Hom.: 0 Cov.: 32 AF XY: 0.0000537 AC XY: 4AN XY: 74476
GnomAD4 genome
AF:
AC:
8
AN:
152320
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74476
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ExAC
AF:
AC:
9
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:5
Uncertain significance, criteria provided, single submitter | clinical testing | GeneKor MSA | Aug 01, 2018 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | True Health Diagnostics | Jan 05, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 03, 2024 | The p.R165W variant (also known as c.493C>T), located in coding exon 6 of the RAD51D gene, results from a C to T substitution at nucleotide position 493. The arginine at codon 165 is replaced by tryptophan, an amino acid with dissimilar properties. This alteration was identified in an individual diagnosed with breast and/or ovarian cancer who previously tested negative for a known familial BRCA1/2 mutation (Dominguez-Valentin M et al. Hered Cancer Clin Pract 2018 Jan;16:4). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 27, 2022 | This missense variant replaces arginine with tryptophan at codon 165 of the RAD51D protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer, together with a pathogenic truncation variant in the ATM gene (PMID: 29371908). This variant has been reported in an unaffected control individual in a breast and ovarian cancer case-control study (PMID: 21822267). This variant has been identified in 13/279074 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 13, 2021 | - - |
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 11, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26261251, 31159747, 32579932, 29371908, 21822267, 21111057, 14704354, 34284872, 33471991, 36243179) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 05, 2024 | The RAD51D c.493C>T (p.Arg165Trp) variant has been reported in the published literature in individuals with breast cancer and a personal and/or family history of breast and/or ovarian cancer (PMID: 29371908 (2018), 31159747 (2019), 33471991 (2021)), see also LOVD (http://databases.lovd.nl/shared/genes/RAD51D). It has also been observed in reportedly healthy individuals (PMIDs: 21822267 (2011), 26261251 (2015), 33471991 (2021)), see also LOVD (http://databases.lovd.nl/shared/genes/RAD51D), 36243179 (2022)). The frequency of this variant in the general population, 0.00012 (3/24306 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2021 | - - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 12, 2023 | Variant summary: RAD51D c.493C>T (p.Arg165Trp) results in a non-conservative amino acid change located in the DNA recombination and repair protein Rad51-like, C-terminal domain; DNA recombination and repair protein RecA-like, ATP-binding domain; AAA+ ATPase domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.6e-05 in 259332 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in RAD51D causing Hereditary Breast And Ovarian Cancer Syndrome (4.6e-05 vs 0.00013), allowing no conclusion about variant significance. c.493C>T has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (Dominguez-Valentin_2018 and Krivokuca_2022). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. Co-occurrences with other pathogenic variant(s) have been reported (ATM c.9139C>T, p.Arg3047Ter), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 21822267, 26261251, 29371908, 34284872). Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified as VUS (n=9) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Feb 06, 2024 | - - |
Breast-ovarian cancer, familial, susceptibility to, 4 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 26, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 165 of the RAD51D protein (p.Arg165Trp). This variant is present in population databases (rs544654228, gnomAD 0.01%). This missense change has been observed in individual(s) with RAD51D-related conditions (PMID: 31159747, 34284872). ClinVar contains an entry for this variant (Variation ID: 127891). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RAD51D protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Lynch syndrome 1 Pathogenic:1
Likely pathogenic, flagged submission | clinical testing | Clinical Cancer Genetics and Family Consultants, Athens Medical Center | Jun 05, 2019 | This variant is denoted RAD51D c.493C>T at the DNA level, p.Arg165Trp. The arginine residue is weakly conserved and there is a moderate physicochemical difference between Arginine and Tryptophan. This variant has not been reported in the literature in individuals with RAD51D related disease. It has never been reported so far in Greek population. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. We observed this variant in a woman with ovarian cancer at the age of 44 years and her brother with undifferentiated gastric cancer at the age of 43 years. Two other sisters are healthy carriers at the age of 53 and 50 years. There was also ovarian and prostate cancer in second degree family members, from the paternal side. The phenotype in this family was consistent with Lynch Syndrome type II. This inherited syndrome in the above family has apparently a causative relation with RAD51D mutation c.493C>T, which is classified as likely pathogenic. - |
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Mar 13, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Benign
DEOGEN2
Benign
.;.;T;T;.;.;.;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;.;D;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;.;L;L;.;.;.;.
PROVEAN
Uncertain
.;.;D;D;.;.;.;.
REVEL
Benign
Sift
Uncertain
.;.;D;D;.;.;.;.
Sift4G
Uncertain
D;D;D;D;D;D;D;.
Polyphen
0.96, 1.0
.;.;D;D;D;.;.;.
Vest4
MutPred
0.53
.;.;Loss of disorder (P = 0.0172);Loss of disorder (P = 0.0172);.;.;.;.;
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at